Aurobindo Pharma Ltd has received final approval from the US Food and Drug Administration (USFDA) to manufacture Atomoxetine capsules.
The approved product is the 'AB’ rated generic equivalent of Eli Lilly and Company’s Strattera capsules indicated for the treatment of attention-deficit/hyperactivity disorder. It had an estimated market size of $1.1 billion for the 12 months ended March 2017, according to IMS.
"The product will be launched immediately,’’ the Hyderabad-based Aurobindo said in a release issued here on Wednesday.
This is the 116th ANDA (including 14 tentative approvals) to be approved out of Unit III formulation facility in Hyderabad.
Aurobindo shares were trading down by 1.49 per cent at Rs 571.50 on the BSE..